In an academic CAR-T program in Uruguay, researchers implemented a multiparametric flow cytometry workflow to monitor anti-CD19 CAR-T cell presence alongside B-cell aplasia and T-cell phenotypes. The setup uses direct anti-CD19 CAR-T detection and functional companion measures to support treatment monitoring beyond a single marker readout. For emerging CAR-T centers, the study illustrates how to standardize analytics in limited-resource settings while improving interpretability of manufacturing and response-associated dynamics.